[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know",
    "summary": "In the latest trading session, Pfizer (PFE) closed at $25.23, marking a -1.33% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=af15fac76737b635fa7f97a6493ba843b5f5c6681f4dafa55b8e8273caf99ff4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733957118,
      "headline": "Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know",
      "id": 131924905,
      "image": "https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the latest trading session, Pfizer (PFE) closed at $25.23, marking a -1.33% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=af15fac76737b635fa7f97a6493ba843b5f5c6681f4dafa55b8e8273caf99ff4"
    }
  },
  {
    "ts": null,
    "headline": "Health execs reckon with patient outrage after UnitedHealthcare killing",
    "summary": "Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health insurance executive was murdered last week, executives from drugmaker Pfizer and Amazon.com said at a panel at the Reuters NEXT conference in New York on Wednesday.  \"Our health system needs to be better ... There's a lot of things that should cause a lot of outrage,\" Amazon Pharmacy Chief Medical Officer Vin Gupta said.  Brian Thompson, the CEO of UnitedHealth's insurance arm, one of the largest health insurers in the U.S., was shot dead on the morning of Dec. 4 outside a hotel in Manhattan in what police said was a targeted attack.",
    "url": "https://finnhub.io/api/news?id=eac8495dec246b696eb3265e5cef6e961995ad2527aa4522b730dacf59856b3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733937786,
      "headline": "Health execs reckon with patient outrage after UnitedHealthcare killing",
      "id": 131924906,
      "image": "https://media.zenfs.com/en/reuters.com/212fb267f1ff6ff12c8b67e9fa582e49",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health insurance executive was murdered last week, executives from drugmaker Pfizer and Amazon.com said at a panel at the Reuters NEXT conference in New York on Wednesday.  \"Our health system needs to be better ... There's a lot of things that should cause a lot of outrage,\" Amazon Pharmacy Chief Medical Officer Vin Gupta said.  Brian Thompson, the CEO of UnitedHealth's insurance arm, one of the largest health insurers in the U.S., was shot dead on the morning of Dec. 4 outside a hotel in Manhattan in what police said was a targeted attack.",
      "url": "https://finnhub.io/api/news?id=eac8495dec246b696eb3265e5cef6e961995ad2527aa4522b730dacf59856b3f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns",
    "summary": "Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with ongoing Seagen acquisition. Read why PFE is a Buy.",
    "url": "https://finnhub.io/api/news?id=eb6b38039a4e085085e59ae062f0a0ac51bbcdc1a9f9f3d9d58d74072ff22093",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733935822,
      "headline": "Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns",
      "id": 131922102,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491484031/image_1491484031.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with ongoing Seagen acquisition. Read why PFE is a Buy.",
      "url": "https://finnhub.io/api/news?id=eb6b38039a4e085085e59ae062f0a0ac51bbcdc1a9f9f3d9d58d74072ff22093"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=cb2edcd717f6124db6c0a0aa74a53b01d95d6e6f3d5a4c92c67e693998fb16de",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733935140,
      "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "id": 131935412,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=cb2edcd717f6124db6c0a0aa74a53b01d95d6e6f3d5a4c92c67e693998fb16de"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates",
    "summary": "The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.",
    "url": "https://finnhub.io/api/news?id=75ede7b1201b5c8acf28721014ac424b2e2a29fee1b612ae1595eb810bc7640e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733930700,
      "headline": "FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates",
      "id": 131923511,
      "image": "https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.",
      "url": "https://finnhub.io/api/news?id=75ede7b1201b5c8acf28721014ac424b2e2a29fee1b612ae1595eb810bc7640e"
    }
  },
  {
    "ts": null,
    "headline": "CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study",
    "summary": "Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.",
    "url": "https://finnhub.io/api/news?id=b8478d7c3e0d669ae0a215924ce3b85812d7d975b0b5cc45c99c6700e1293927",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733929500,
      "headline": "CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study",
      "id": 131924908,
      "image": "https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.",
      "url": "https://finnhub.io/api/news?id=b8478d7c3e0d669ae0a215924ce3b85812d7d975b0b5cc45c99c6700e1293927"
    }
  },
  {
    "ts": null,
    "headline": "QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug",
    "summary": "uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.",
    "url": "https://finnhub.io/api/news?id=182064d56d186cff8b384f557c5d0c2abfb15de4091047e9d454f57adaad4a20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733929320,
      "headline": "QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug",
      "id": 131924909,
      "image": "https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.",
      "url": "https://finnhub.io/api/news?id=182064d56d186cff8b384f557c5d0c2abfb15de4091047e9d454f57adaad4a20"
    }
  },
  {
    "ts": null,
    "headline": "GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade",
    "summary": "GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.",
    "url": "https://finnhub.io/api/news?id=bc0b605c06f5ec3f98279311a1ef2ad99e74f82411ec1575d2b239bcddd8ccff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733926080,
      "headline": "GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade",
      "id": 131921371,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1448400357/image_1448400357.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.",
      "url": "https://finnhub.io/api/news?id=bc0b605c06f5ec3f98279311a1ef2ad99e74f82411ec1575d2b239bcddd8ccff"
    }
  },
  {
    "ts": null,
    "headline": "NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines",
    "summary": "Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.",
    "url": "https://finnhub.io/api/news?id=b62a7f5b3592fb90811ac59883cfb9dd8de5f1376a075bcbea4ec52d017c2c72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733921400,
      "headline": "NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines",
      "id": 131923512,
      "image": "https://media.zenfs.com/en/zacks.com/5ef34b229359328ddb52bd15cfa3b6b2",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.",
      "url": "https://finnhub.io/api/news?id=b62a7f5b3592fb90811ac59883cfb9dd8de5f1376a075bcbea4ec52d017c2c72"
    }
  },
  {
    "ts": null,
    "headline": "Pioneer Disciplined Value Fund Q3 2024 Performance And Market Commentary",
    "summary": "Pioneer Disciplined Value focuses on mispriced quality, sustainable US large-cap companies trading at attractive valuations with the goal of maximizing risk-adjusted returns.",
    "url": "https://finnhub.io/api/news?id=d4f3261fd93e6b78ad690012a471451ef57fa7e1bbef1712c590cb1c6e72d1b3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733920800,
      "headline": "Pioneer Disciplined Value Fund Q3 2024 Performance And Market Commentary",
      "id": 131921068,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152882467/image_2152882467.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pioneer Disciplined Value focuses on mispriced quality, sustainable US large-cap companies trading at attractive valuations with the goal of maximizing risk-adjusted returns.",
      "url": "https://finnhub.io/api/news?id=d4f3261fd93e6b78ad690012a471451ef57fa7e1bbef1712c590cb1c6e72d1b3"
    }
  },
  {
    "ts": null,
    "headline": "Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Ka Inhibitor STX-478",
    "summary": "BOSTON - Scorpion Therapeutics, Inc. , a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer, today presented updated analyses from its...",
    "url": "https://finnhub.io/api/news?id=07d02554ddadc577b64e111ff03a7e4c9ce8753b1cf49ac8cd7b1b63cd6a12b4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733916871,
      "headline": "Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Ka Inhibitor STX-478",
      "id": 131920724,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "BOSTON - Scorpion Therapeutics, Inc. , a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer, today presented updated analyses from its...",
      "url": "https://finnhub.io/api/news?id=07d02554ddadc577b64e111ff03a7e4c9ce8753b1cf49ac8cd7b1b63cd6a12b4"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial",
    "summary": "The combination demonstrated a tolerable safety profile, as per the trial’s preliminary data involving 16 subjects.",
    "url": "https://finnhub.io/api/news?id=74e626741c66b896a637ce6ac05a4a3213eca47d94482b5d3e46be520327e9ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733913505,
      "headline": "Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial",
      "id": 131917796,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/CTA-1-PfizerArvinas-Shutterstock_1402173971.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The combination demonstrated a tolerable safety profile, as per the trial’s preliminary data involving 16 subjects.",
      "url": "https://finnhub.io/api/news?id=74e626741c66b896a637ce6ac05a4a3213eca47d94482b5d3e46be520327e9ec"
    }
  },
  {
    "ts": null,
    "headline": "Broad Market Gains Shape Moat Strategies For 2025",
    "summary": "U.S. equities soared in November, with small caps leading the rally. Moat strategies benefitted from strong earnings, but faced headwinds from sector allocations.",
    "url": "https://finnhub.io/api/news?id=54e02a482a39c8bda0e32f7d645d201345a311cc6ec2bf1c8f89c42d9b636254",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733894400,
      "headline": "Broad Market Gains Shape Moat Strategies For 2025",
      "id": 131916376,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1705145695/image_1705145695.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "U.S. equities soared in November, with small caps leading the rally. Moat strategies benefitted from strong earnings, but faced headwinds from sector allocations.",
      "url": "https://finnhub.io/api/news?id=54e02a482a39c8bda0e32f7d645d201345a311cc6ec2bf1c8f89c42d9b636254"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Best American Dividend Stock to Buy Right Now?",
    "summary": "We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other American dividend stocks. The US economy expanded by 2.8% in the third quarter of 2024, as reported in the Advance GDP […]",
    "url": "https://finnhub.io/api/news?id=131b33de06e17db700530fd00a9b2d963d3eb9132ae54c6da16c990c9ed35475",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733891961,
      "headline": "Is Pfizer Inc. (PFE) the Best American Dividend Stock to Buy Right Now?",
      "id": 131924912,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other American dividend stocks. The US economy expanded by 2.8% in the third quarter of 2024, as reported in the Advance GDP […]",
      "url": "https://finnhub.io/api/news?id=131b33de06e17db700530fd00a9b2d963d3eb9132ae54c6da16c990c9ed35475"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)",
    "summary": "Pfizer has a diversified portfolio, including successful vaccines and promising new drugs. Read more to see why I upgrade PFE stock to Strong Buy.",
    "url": "https://finnhub.io/api/news?id=5e945f5198808874271b1caba6b6d24588780d2b3b457f5d05791bf3a7acf0e6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733886370,
      "headline": "Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)",
      "id": 131914357,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491484031/image_1491484031.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer has a diversified portfolio, including successful vaccines and promising new drugs. Read more to see why I upgrade PFE stock to Strong Buy.",
      "url": "https://finnhub.io/api/news?id=5e945f5198808874271b1caba6b6d24588780d2b3b457f5d05791bf3a7acf0e6"
    }
  }
]